🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for CD19-positive Relapsed or Refractory B-cell Malignancies

SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site📍 Hong Kong Hong Kong Children's Hospital · Tests: CAR-T Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD19/CD22-CAR T cells Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies NCT05705570Phase 11 site📍 São Paulo Nelson Hamerschlak · Tests: Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day… Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. NCT06092047EARLY Phase 11 site📍 Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Tests: UTAA09 cells for infusion, Fludarabine, Cyclophosphamide CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma NCT06834529Phase 1, Phase 21 site📍 Beijing Affiliated Hospital to Academy of Military Medical Sciences · Tests: CAR2219-T cells A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) NCT06287528Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: 19-28z/IL-18 CAR T cells A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia NCT07429461EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: SYNCAR-100 Injection Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma NCT06047197Phase 11 site📍 Tianjin Beijing Yongtai Ruike Biotechnology Company Ltd · Tests: RC19D2 cell injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy